ZNF295-AS1: ZNF295-AS1 is a long non-coding RNA (lncRNA) that has been implicated in the pathogenesis of epithelial ovarian cancer [PMC7168724]. In a study, the enrichment of pathways associated with ZNF295-AS1 was found to be zero, unlike other lncRNAs [PMC7168724]. A lncRNA-miRNA-mRNA network was created, which included ZNF295-AS1 and other lncRNAs, miRNAs, and mRNAs [PMC7168724]. The expression levels of ZNF295-AS1 and other co-expressed lncRNAs were detected using qRT-PCR to validate RNA-seq data [PMC8005612]. ZNF295-AS1 was identified as a differentially expressed lncRNA in ovarian cancer using miRcode analysis [PMC7377077]. Based on the role of ZNF295 as a transcriptional repressor, it is suggested that ZNF295-AS1 may be involved in the regulation of gene expression related to tumorigenesis [PMC5747377]. ZNF295-AS1 was identified as one of the interesting candidate lncRNAs for further analysis based on its features such as fold difference and gene locus [PMC4121291]. The expression levels of ZNF295-AS1 were found to be up-regulated on promoters in liver cancer cells mediated by HBx-mediated H3K9me3 enrichments [PMC5356706]. In a study investigating ceRNA networks associated with gefitinib resistance, MIR137HG and ZNF295-AS1 were identified as promising lncRNAs associated with gefitinib resistance in lung adenocarcinoma cells [PMC9477152]. The expression pattern of MIR137HG and ZNF295-AS1 showed similarity to FZD4 in the ceRNA subnetwork [PMC9477152]. ZNF295-AS1 was found to be down-regulated in glioma and associated with glioma grade and survival [PMC9980576]. Additionally, ZNF295-AS1 was found to be down-regulated in a study on colorectal cancer [PMC9436424].